Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV hyperimmune globulin plus ganciclovir for CMV viremia after allogeneic hematopoietic stem cell transplantation
CTR20192005Phase 2Active
- Sponsor
- Shandong Taibang Biological Products
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of human cytomegalovirus immune globulin, ganciclovir in cytomegalovirus infection, cytomegalovirus disease (CMV), sponsored by Shandong Taibang Biological Products. Started Sep 2020; status: active.
02
Drugs
human cytomegalovirus immune globulinganciclovir
03
Conditions
cytomegalovirus infectioncytomegalovirus disease (CMV)
Beyond the preview
Go deeper on CTR20192005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192005.